| Drug Name |
Pirfenidone |
| Drug ID |
BADD_D01783 |
| Description |
Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune. |
| Indications and Usage |
For the treatment of idiopathic pulmonary fibrosis (IPF). |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L04AX05 |
| DrugBank ID |
DB04951
|
| KEGG ID |
D01583
|
| MeSH ID |
C093844
|
| PubChem ID |
40632
|
| TTD Drug ID |
D02WCI
|
| NDC Product Code |
65372-1197; 46708-907; 73309-052; 46016-5310; 62207-004; 62512-0070; 69037-0013; 53104-7712; 11014-0214; 59285-013; 76072-1006; 69766-030; 50242-122; 57297-140; 46016-5312; 46438-0648; 60219-1642; 50242-121; 50242-123; 59651-199; 60219-1640; 60219-1641; 60862-005; 42571-329; 63759-7005 |
| Synonyms |
pirfenidone | 5-methyl-1-phenyl-2-(1H)-pyridone | Esbriet | deupirfenidone | 1-phenyl-5-(trideuteriomethyl)-1,2-dihydropyridin-2-one | Deskar |
